NCT07875959Recruiting
18F-N230A PET/CT Imaging of Nectin-4 Expression in Renal Tumors
A Study to Evaluate 18F-N230A PET/CT Imaging of Nectin-4 Expression in Patients With Renal Cell Carcinoma and Renal Pelvic Urothelial Carcinoma
Source: ClinicalTrials.gov · Last updated 15 Oct 2026
Brief summary (registry, in English)
Renal cell carcinoma and renal pelvic urothelial carcinoma are common malignant tumors of the urinary system. Accurate preoperative differentiation between these tumor types is important for treatment planning, while conventional imaging methods may have limitations in characterizing tumor biology. Nectin-4 is a tumor-associated molecular target that is highly expressed in several epithelial malignancies, particularly urothelial carcinoma. 18F-N230A is a novel PET imaging probe targeting Nectin-4. This study aims to evaluate the safety, biodistribution, and imaging characteristics of 18F-N230A PET/CT in patients with suspected or confirmed renal tumors. Participants enrolled in this study will undergo 18F-N230A PET/CT imaging and 18F-FDG PET/CT imaging. The imaging findings and quantitative parameters will be analyzed and compared. Pathological results obtained from surgery or biopsy will be used as the reference standard to evaluate the potential value of 18F-N230A PET/CT in differentiating renal cell carcinoma from renal pelvic urothelial carcinoma. This study may provide a new molecular imaging approach for improving the preoperative diagnosis of renal tumors and supporting individualized clinical decision-making.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 9 Aug 2026
- Start date
- 9 Jul 2026
- Primary completion date
- 31 Dec 2028
- Lead sponsor
- Peking University First Hospital
- Diseases
- Kidney cancer, Bladder cancer
- NCT number
- NCT07875959
What you commit to
- Study type: Interventional
- Planned participants: 80
- From 9 Jul 2026 to the primary completion date, 31 Dec 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with a history of other malignant tumors.
Lab values
- Patients with severe abnormalities in liver function, renal function, or blood cell counts.
Other
- Patients unable to understand the study procedures or unable to cooperate with imaging examinations.
- Patients considered unsuitable for participation by the investigator.
Who the study is looking for
- Participants aged ≥18 years.
- Patients with suspected or confirmed renal tumors who are scheduled for pathological examination by biopsy or surgical resection within 2 months.
- Patients who can understand the study procedures and voluntarily provide written informed consent.
- Patients who can cooperate with PET/CT imaging procedures.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking University First Hospital Coordinator of this site? Confirm its status | Beijing | China | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.